Background/Aims: The notion that acute hepatitis A superimposed on chronic hepatitis B infection leads to a worse outcome than acute hepatitis A alone remains controversial. The aim of this study was to determine the infl uence of the presence of hepatitis B surface antigen (HBsAg) on the severity of acute hepatitis A. Methods: We retrospectively analyzed 449 patients hospitalized for acute hepatitis A from January 2000 to February 2010 and compared clinical outcomes based on the presence of HBsAg. Results: Of the 449 patients, 30 patients were in the HBsAg-positive group and 419 in the HBsAg-negative group. The HBsAg-positive group was older than the HBsAg-negative group (36.1±8.3 vs 31.8±8.5 years, p=0.004); however, other baseline characteristics were similar between the 2 groups. Mean peak values of prothrombin time, serum total bilirubin, and serum creatinine at admission were significantly higher in the HBsAg-positive group. When comparing clinical outcomes between the 2 groups, gastrointestinal bleeding, acute renal failure, and acute liver failure were more frequently observed in the HBsAg-positive group. In particular, the incidence of acute liver failure was approximately 9-fold higher in the HBsAg-positive group than in the HBsAg-negative group (23.3% vs 3.3%; odds ratio [OR], 8.80; p<0.001). Multivariate analysis showed that HBsAg (OR, 7.43; 95% confi dence interval [CI], 2.56 to 21.57) and age (OR, 1.07; 95% CI, 1.02 to 1.13) were independent risk factors for the occurrence of acute liver failure. Conclusions: In patients with chronic hepatitis B infection, acute hepatitis A is associated with more severe clinical outcomes, including acute liver failure, compared with patients with acute hepatitis A alone. (Gut Liver 2011;5:500-505) 
INTRODUCTION
The incidence of acute hepatitis A in Korea has been increasing significantly because the rate of seropositivity of anti-HAV(IgG) has been decreasing with socioeconomic development and improvements in public health and environment. 1 In a recent survey, approximately half of Korean individuals infected with the hepatitis A virus (HAV) had to be hospitalized with acute hepatitis. 2 Most patients with HAV infection have a favorable clinical course and spontaneous recovery, and only a few suffer from serious complications of acute hepatitis A such as acute fulminant hepatitis, acute renal failure, or cholestatic hepatitis. In some previous reports, the clinical course and outcome of hepatitis A in patients with underlying chronic hepatitis B virus (HBV) infection was associated with higher peak laboratory abnormalities and more severe outcomes, including acute liver failure and a higher fatality rate. 3 However, there is controversy over the influence of HBV infection on the outcome of acute hepatitis. Vaccines have been available against hepatitis B and hepatitis A since 1981 and 1995, respectively. 4 Formalin-inactivated hepatitis A vaccination is considered safe and effective in patients with chronic liver disease, including chronic hepatitis B. Nevertheless, in Korea, an area with endemic HAV and HBV infection, hepatitis A has not been designated a mandatory vaccination. In addition, there are very few comparative studies of clinical outcome in acute hepatitis A according to the presence of hepatitis B surface antigen (HBsAg). In this study, we retrospectively compared the clinical outcome of acute hepatitis A between HBsAg-positive and HBsAg-negative patients, and analyzed the incidence of acute liver failure as a measure of the severity of acute hepatitis A.
MATERIALS AND METHODS

Patients
Between January 2000 and February 2010, 452 consecutive patients who were admitted to Samsung Medical Center, Seoul, Korea for acute hepatitis A were retrospectively reviewed. Three patients who were positive for hepatitis C virus (HCV) RNA with anti-HCV were excluded from this study. A total of 449 patients were included and classified into 2 groups: HBsAg-positive group (n=30) and HBsAg-negative group (n=419).
Methods
Acute hepatitis A was diagnosed when patients were hospitalized with typical symptoms of acute viral hepatitis and presence of serum IgM anti-HAV (Abbott, HAV Ab-M). The presence of IgM anti HAV and HBsAg and the absence of IgM anti-HBc established the diagnosis of acute hepatitis A superimposed on a chronic HBsAg carrier. We adjusted the data for age, sex, the route of virus infection, and comorbidity in both positive-HBsAg and negative-HBsAg groups. The following blood tests were performed at the initial time of admission and regularly during admission: hemoglobin, platelet count, prothrombin time (PT), serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum total bilirubin, alkaline phosphatase (ALP), serum albumin, γ-glutamyl transferase (GGT), and serum creatinine. Patients who were HBsAg-positive were compared with patients without HBsAg with respect to complete blood count at the time of admission and the most severe laboratory abnormality of the biochemical profile, including liver function tests, at admission. We also compared the incidences of prolonged jaundice, gastrointestinal bleeding, acute renal failure, acute liver failure, liver transplantation, death, and the mean durations of hospitalization between the 2 groups to determine the differences in clinical outcome. Postoperative hospital stay was included in the estimation of hospitalization time for patients who underwent liver transplantation. Patients were considered to have acute liver failure (ALF) according to the widely accepted definition of ALF, which includes evidence of coagulation abnormality, usually an international normalized ratio (INR) ≥1.5, and any degree of mental alteration (encephalopathy) in a patient without pre-existing cirrhosis and with an illness of <26 weeks duration, with the exception of liver cirrhosis caused by vertically-acquired HBV if the disease has been recognized for <26 weeks. 5 The definition for acute renal failure (ARF) was an increase in serum creatinine concentration ≥0.5 mg/dL or by 50% compared with baseline value. 6 Gastrointestinal bleeding was defined as when patients presented with hematemesis, melena or hematochezia and had a drop in hemoglobin ≥1.5 g/ dL. This study's protocol was approved by the Ethics Committee of Samsung Medical Center and the study was conducted in accordance with the principles of the Declaration of Helsinki. Data are presented as mean±SD or number (%). *Alcoholic intake >40 g/day; Thyroid disease, asthma, epilepsy, pulmonary tuberculosis.
Statistical analysis
RESULTS
Clinical characteristics
Basic characteristics of the 449 patients are shown in Table 1 . Among the 30 patients in the HBsAg-positive group, the males outnumbered the females 22 (73.3%) to 8 (26.7%). Mean age at the time of admission was 36.1 years and 31.8 years in the HBsAg-positive group and HBsAg-negative group, respectively, and the HBsAg-positive group was significantly older than the HBsAg-negative group (p=0.004). In both HBsAg-positive and HBsAg-negative groups, the majority of patients were in the age group of 30 to 39 years. The infection source of acute hepatitis A was almost exclusively unknown origin in both groups (93.3% in the positive group vs 95.0% in the negative group). Two patients in the HBsAg-positive group had liver cirrhosis at the time of admission for acute hepatitis A: one patient had been diagnosed with Child-Pugh class B liver cirrhosis 1 year previously, and the other patient was newly diagnosed with Child-Pugh class A liver cirrhosis. Seven patients of the HBsAgpositive group were HBeAg-positive and 5 of these had received antiviral drugs such as lamivudine for chronic hepatitis B. 
Laboratory fi ndings
We compared the initial values for hemoglobin level and platelet count at the time of admission, and the most severe value of PT, serum albumin, AST, ALT, and serum total bilirubin, which are directly correlated to liver function, during admission between the 2 groups of patients with acute hepatitis A ( .001) during admission were also significantly higher in patients of the HBsAg-positive group. In contrast, the mean values of hemoglobin, serum albumin, AST, ALT, GGT, and serum creatinine did not differ significantly between the HBsAg-positive and HBsAg negative groups.
Clinical outcomes
To evaluate the influence of chronic HBV infection on the severity of acute hepatitis A, the incidences of prolonged jaundice, gastrointestinal bleeding, ARF, ALF, liver transplantation, death, and the mean durations of hospitalization were compared in terms of clinical outcomes between the 2 groups (Table 3) . Of the 30 patients who were carriers of HBsAg, 7 developed ALF. Two of these patients had been taking lamivudine, and the other 5, including 1 patient newly diagnosed with Child-Pugh class A liver cirrhosis, had not received prior treatment. All 7 patients had detectable HBV DNA at the time of admission. HBV DNA level of 7 patients at the time of admission were varied from 65 to 45,919 IU/mL. Two patients who had been taking lamivudine had maintained viral suppression (HBV DNA levels <2,000 IU/ mL). However, 1 of 2 patients showed viral reactivation of HBV replication, which was characterized by HBV DNA levels >2,000 IU/mL, at the time of admission. One of the 2 patients with liver cirrhosis, who had been diagnosed with Child-Pugh class B liver cirrhosis 1 year previously, had a favorable clinical course and spontaneous recovery. The incidence of ALF was significantly higher among patients with acute hepatitis A and chronic HBV infection than among patients with acute hepatitis A alone (23.3% vs 3.3%; odds ratio [OR], 8.80; p<0.001). Among the total 449 patients with acute hepatitis A, 21 patients had ALF, 11 patients underwent liver transplantation, and 4 died secondary to ALF. Among the 10 ALF patients who did not undergo liver transplantation, 2 patients in deep coma died before a donor liver could be found, whereas the other 8 patients recovered spontaneously. Two patients with ALF died in the postoperative period after undergoing liver transplantation. One patient died due to vascular compression caused by huge hematoma around the transplanted liver, and the other died due to primary graft nonfunction. ARF was noted in 46 of 449 patients with acute hepatitis A. With 2 of the deaths from hepatitis A occurring in patients with chronic HBV infection, the case fatality rate in this subset of patients was 6.7%. One of these patients had died after receiving a liver transplant. Among the 46 patients with ARF, 8 were in the HBsAg-positive group and 38 were in the HBsAgnegative group. The incidence of ARF in patients with acute hepatitis A and chronic HBV infection was also significantly higher than in patients with acute hepatitis A alone (OR, 3.64; p=0.007). In comparison of hospitalization time according to the presence of HBsAg, the average duration of hospitalization for the HBsAg-positive and -negative groups was 21.6±4.1 days and 10.0±0.4 days, respectively. Thus, the hospitalization time reflecting the morbidity caused by acute hepatitis A was significantly longer in the HBsAg-positive group than in the HBsAgnegative group (p=0.007).
To evaluate the potential risk characteristics of acute hepatitis A-associated ALF, we performed multivariate analysis. Table 4 shows odds ratios for the incidence of ALF associated with acute hepatitis A based on covariates that include age, sex, HBsAg, comorbidity, and excessive alcohol consumption. Logistic regression analysis showed that HBsAg positivity (OR, 7.43; 95% confidence interval [CI], 2.56 to 21.57) and age (OR, 1.07; 95% CI, 1.02 to 1.13) were independent predictors for the occurrence of ALF. Other factors such as sex, comorbidity, and excessive alcohol consumption were not significant.
DISCUSSION
ALF is a rare complication of HAV infection. Fulminant hepatitis in HAV infection occurs in approximately 0.1% to 0.5% of cases. 7 HAV infections in the Korean adult population have been increasing considerably due to the decreased opportunity for HAV infection in younger individuals. 8 As a result, a higher frequency of clinically severe hepatitis, including ALF, has been observed. In addition, the increase in HAV infection in adults has resulted in a relative increase in the number of cases of acute hepatitis A among HBsAg carriers. HAV-related liver disease is known to be caused by immunologic mechanisms rather than direct toxicity of the virus. 9 INF-γ produced by HAV-specific T cells may play an important role in the pathogenesis of infection. 10 During infection with HAV and HBV, it is possible that INF-γ produced in response to HAV stimulus has an antiviral effect on HBV infection. It has also been reported that HAV superinfection in patients with chronic hepatitis B suppresses hepatitis B viral replication. [11] [12] [13] However, because a reduction in HBV viral load is associated with an increase in the immune response of the host, in some cases an excessive host response may induce severe damage of hepatocytes. Although their study was not on hepatitis B, Cacopardo et al. 14 suggested that HAV and HCV-related liver cell damage and viral clearance might be mediated by HAV-specific T cell responses with enhanced production of INF-γ. Several studies have reported that HAV superinfection in patients with pre-existing liver disease is associated with a high rate of morbidity and mortality. [15] [16] [17] [18] [19] However, not all reported studies are consistent with this view. Some reports have indicated that new HAV infections in patients with chronic viral hepatitis showed no hepatic decompensation and were similar to those of patients with hepatitis A alone. [20] [21] [22] Regarding superinfection with HAV in patients with hepatitis B virus, the clinical implications are more controversial. 23 revealed that, unlike patients with chronic hepatitis C, most patients with chronic hepatitis B who acquired HAV infections had uncomplicated courses. In addition, no cases of fulminant hepatitis or death were observed in a retrospective study of 177 Korean patients with acute hepatitis A, including 10 HBsAg-positive patients. 24 In our study, there were higher prevalences of ALF, emergency liver transplantation for ALF, and ARF among the patients with acute HAV superimposed on chronic HBV infection, and our data also showed that these patients were associated with higher peak laboratory abnormalities and longer hospital stays. The present study confirmed previous findings that acute HAV infection could cause severe liver injury in patients with chronic HBV infection. Whether the presence of HBsAg itself has a negative effect on clinical outcomes of acute hepatitis A is open to dispute. Several studies suggest that the severity of acute hepatitis A is correlated to the severity of the underlying chronic HBV infection since the risk from hepatitis A is increased in the presence of chronic hepatitis or liver cirrhosis, compared with healthy HBsAg carriers. 9, 25 This explanation of the conflicting influence of chronic hepatitis B infection on clinical features of acute hepatitis A has become the commonly accepted view. However, in the majority of cases it is hard to determine the state of the HBsAg carrier (for example healthy carrier, chronic hepatitis, or liver cirrhosis) at the time of treatment for acute hepatitis A, because in most cases the state of their liver has not been regularly checked. In our study, only seven HBsAgpositive patients, including five patients who had been treated for chronic hepatitis B, had been followed up with their doctors. Therefore, we are not convinced that there is no substantial risk of fulminant hepatitis in healthy HBsAg carriers. In Korea, an area with a high prevalence of HBV infection, a progressive decrease in natural immunity against HAV has been observed. Moreover, the seroprevalance of HAV infection in patients with chronic liver disease is similar to that in the general population classified by age. 26, 27 Therefore we suggest that individuals with chronic HBV infection should be considered as candidates for anti-HAV vaccination, especially as the HAV vaccine is known to be equally safe in patients with chronic liver diseases and the general population. 28 In conclusion, our study indicates that acute hepatitis A superimposed on chronic HBV infection is associated with serious morbidity and mortality. Especially in terms of ALF, HBsAgpositive patients with acute hepatitis A are at an approximately nine-fold increased risk. Increasing age is known to be related to increased HAV morbidity and mortality, as well as underlying liver disease. Indeed, in our study the incidence of ALF was significantly associated with advanced age; however, when we performed multiple regression analysis the statistical significance of age was reduced compared with the significance of the presence of HBsAg. The main shortcomings of the present study are its retrospective nature and the fact that the study was conducted in a tertiary referral hospital, therefore there may be selection bias for patients who were referred for intensive care or liver transplantation. In other words, there may be a possibility that when patients with acute HAV infection were expected to have a poor prognosis, these patients were likely to be referred to specialty hospital for liver transplantation. Despite these, our study is significant in the sense that it is one of few analyses on the difference in clinical features between HBsAg-positive and HBsAg-negative patients in this HBV endemic area. Furthermore, the results of this study also indicate that acute hepatitis A is no longer a mild disease, at least in HBsAg carriers.
